You need to login...
If you are not registered...
| Subscribe to Cancer Stat: | |
|
or call us on: +44 (0)20 7769 6707 or email: apus@templetonapus.com |
|
Most viewed
- 1. US Cancer Biosimilar Market Size Sales Opportunity Oncology Biosimilars Clinical Trials Outlook 2026
- 2. Roche joins the FDA accelerated approval revamp team, nixing a Tecentriq bladder cancer nod
- 3. CytoDyn to Hold Webcast on March 8 to Provide Overview of CD12 Trial Data and Regulatory Path Forward with the U.S., U.K., Canada, Philippines and Brazil
- 4. CytoDyn's Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab
- 5. CytoDyn to File Accelerated Rolling Review with MHRA and Interim Order (IO) with Health Canada for COVID-19
- 6. STAT+: CytoDyn's wild weekend of data-mining study results ends in failure for its Covid treatment
- 7. Reirradiation by Nanoparticles and Hypofractionated Protontherapy of Relapses Tumors: Non-randomized Phase II Study.
- 8. Clinical Validation of Cervical Cancer Screening Methods
- 9. In France, there's no escape from Covid vaccine sceptics. What would Pasteur think?
- 10. Surgeons fear wave of lawsuits over delays to cancer treatment
Last updated at 15:53 GMT
Hot News Makers
Health/Pharma Companies
-
21982.32
-
16485.66
-
15394.25
-
14758.71
-
13847.63
-
13518.48
-
13350.20
-
12666.65
-
11872.32
-
11032.40
Last updated at 15:10 GMT
© Copyright 2021 Templeton Apus. All rights reserved.
Made with 
and
in the EU & the UK
and
in the EU & the UK